TG Therapeutics touts safer PI3Kδ inhibitor as execs tout PhII data, hunt quick OK for a tough niche
Eyeing an expedited FDA approval, TG Therapeutics unveiled data from a Phase II PI3Kδ trial. They say it shows effectiveness against follicular lymphoma without the severe adverse effects that have plagued PI3Kδ treatments to date.
TG reported that it met the goal of having 40-50% of the 118 follicular lymphoma patients treated with umbralisib respond to the drug. The single-agent study was specifically designed to model the studies that brought accelerated FDA approval for other PI3Kδ drugs, TG CEO Michael Weiss said in a conference call yesterday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.